1. CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1–Dependent IGF-1 Signaling
- Author
-
Sun, Haibo, Lin, De-Chen, Cao, Qi, Guo, Xiao, Marijon, Helene, Zhao, Zhiqiang, Gery, Sigal, Xu, Liang, Yang, Henry, Pang, Brendan, Lee, Victor Kwan Min, Lim, Huey Jin, Doan, Ngan, Said, Jonathan W, Chu, Peiguo, Mayakonda, Anand, Thomas, Tom, Forscher, Charles, Baloglu, Erkan, Shacham, Sharon, Rajalingam, Raja, and Koeffler, H Phillip
- Subjects
Pediatric ,Pediatric Cancer ,Rare Diseases ,Cancer ,Biotechnology ,Genetics ,Animals ,Antineoplastic Combined Chemotherapy Protocols ,Apoptosis ,Bone Neoplasms ,Cell Line ,Tumor ,Cell Survival ,Drug Synergism ,Female ,Gene Knockdown Techniques ,Humans ,Hydrazines ,Imidazoles ,Immunoblotting ,Immunohistochemistry ,Insulin-Like Growth Factor I ,Karyopherins ,Mice ,Mice ,Nude ,Oncogene Proteins ,Fusion ,Proto-Oncogene Protein c-fli-1 ,Pyrazines ,RNA-Binding Protein EWS ,Real-Time Polymerase Chain Reaction ,Receptors ,Cytoplasmic and Nuclear ,Sarcoma ,Ewing ,Signal Transduction ,Triazoles ,Xenograft Model Antitumor Assays ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Ewing sarcoma (EWS) is an aggressive bone malignancy that mainly affects children and young adults. The mechanisms by which EWS (EWSR1) fusion genes drive the disease are not fully understood. CRM1 (XPO1) traffics proteins from the nucleus, including tumor suppressors and growth factors, and is overexpressed in many cancers. A small-molecule inhibitor of CRM1, KPT-330, has shown therapeutic promise, but has yet to be investigated in the context of EWS. In this study, we demonstrate that CRM1 is also highly expressed in EWS. shRNA-mediated or pharmacologic inhibition of CRM1 in EWS cells dramatically decreased cell growth while inducing apoptosis, cell-cycle arrest, and protein expression alterations to several cancer-related factors. Interestingly, silencing of CRM1 markedly reduced EWS-FLI1 fusion protein expression at the posttranscriptional level and upregulated the expression of the well-established EWS-FLI1 target gene, insulin-like growth factor binding protein 3 (IGFBP3), which inhibits IGF-1. Accordingly, KPT-330 treatment attenuated IGF-1-induced activation of the IGF-1R/AKT pathway. Furthermore, knockdown of IGFBP3 increased cell growth and rescued the inhibitory effects on IGF-1 signaling triggered by CRM1 inhibition. Finally, treatment of EWS cells with a combination of KPT-330 and the IGF-1R inhibitor, linsitinib, synergistically decreased cell proliferation both in vitro and in vivo Taken together, these findings provide a strong rationale for investigating the efficacy of combinatorial inhibition of CRM1 and IGF-1R for the treatment of EWS. Cancer Res; 76(9); 2687-97. ©2016 AACR.
- Published
- 2016